Gut Dysbiosis for TMAO Production From Red Meat Consumption
Conditions
Keywords
TMAO, red meat, carnitine, gut microbiota, gbu gene cluster, cardiovascular disease
Brief summary
The risk of cardiovascular diseases from red meat consumption varies among individuals due to variations in gut microbiota. L-carnitine in red meat can be converted to Trimethylamine n-oxide (TMAO) in the body by certain bacteria. Not everyone experiences a significant increase in TMAO levels after consuming carnitine. Gut microbiota differences are observed between high and low TMAO producers. The presence of the γ-butyrobetaine utilization (gbu) gene in gut microbiota is linked to TMAO production. This clinical research aims to determine if the gbu gene can predict TMAO levels after intaking a large amount of red meat.
Detailed description
The risk of developing cardiovascular diseases due to the consumption of red meat varies among individuals, and this may be attributed to differences in the composition and function of gut microbiota. Studies have found that red meat, rich in L-carnitine, may be metabolized by certain anaerobic bacteria in the intestines to produce trimethylamine N-oxide (TMAO) in the human body. Previous research utilizing the oral carnitine challenge test (OCCT) revealed that not everyone experiences a significant increase in blood TMAO levels after consuming carnitine. Moreover, individuals with high TMAO production and low TMAO production showed distinct differences in their gut microbiota. Furthermore, we have discovered a significant correlation between the abundance of the gbu gene in gut microbiota and the production of TMAO in response to dietary carnitine intake. Therefore, through the design of clinical research, we aim to investigate and assess whether the abundance of the gbu gene in gut microbiota can predict the levels of TMAO produced in the human body under a large amount of red meat consumption.
Interventions
900 grams of lean beef
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult with age between 18 to 70 * Willing and capable of intaking a large amount of beef
Exclusion criteria
* Antibiotics use within one month * L-carnitine supplement use within one month * Chronic diarrhea * Myasthenia gravis * Parathyroid disorders * Chronic kidney disease * Epilepsy * Severe anemia * Severe cardiovascular diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal gbu gene abundance measured by qPCR | up to 7-10 days |
| Blood TMAO level measured by LC-MS/MS | before intervention, 24hr, 48hr after intervention |
| Platelet aggregation of blood by Light Transmission Aggregometry | up to 7-10 days |
| Gut microbiome profiles measured by shotgun metagenome sequencing | up to 7-10 days |
Secondary
| Measure | Time frame |
|---|---|
| Carnitine intake measured by 24hr dietary record | up to 7-10 days |
Countries
Taiwan